Ipamorelin: How the Selective GH Secretagogue Works

What Is Ipamorelin?

Ipamorelin (CAS 170851-70-4, molecular formula C₃₈H₄₉N₉O₅, molecular weight 711.85 Da) is a synthetic pentapeptide that belongs to the growth hormone secretagogue (GHS) class of research compounds. Its sequence — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — incorporates two non-natural amino acids that are critical to its pharmacological profile:

• •Aib (alpha-aminoisobutyric acid) at position 1 improves metabolic stability
• •D-2-Nal (D-2-naphthylalanine) at position 3 enhances GHS-R1a receptor selectivity

Ipamorelin is classified as a third-generation GHRP (growth hormone-releasing peptide). It works by agonising GHS-R1a — the ghrelin receptor — on pituitary somatotroph cells, triggering the release of natural, pulsatile growth hormone.

The GHRP Evolution: Why Selectivity Matters

Understanding Ipamorelin requires understanding why earlier compounds were inadequate for clean GH research:

GHRP-6 (first generation): Effective GH stimulator but substantially elevates cortisol (stress hormone), prolactin, and appetite via off-target receptor activity. These co-secreted hormones confound experiments studying isolated GH effects.

GHRP-2 (second generation): More potent than GHRP-6, but cortisol elevation remains a significant issue. Useful where GH output is the sole priority, but problematic for protocols studying metabolism, stress, or immune function.

Ipamorelin (third generation): Designed specifically for receptor selectivity. In head-to-head preclinical studies, Ipamorelin produces comparable or superior GH pulse amplitude to earlier GHRPs with near-zero cortisol or prolactin co-secretion. This makes it the preferred research tool when isolated GH axis data is required.

Key Research Areas

Growth Hormone Pulse Stimulation

Ipamorelin's primary studied effect is clean, pulsatile GH release from the anterior pituitary. The pulse pattern mimics the body's natural physiological GH pulsatility rather than producing a sustained flat elevation — which is important for research into GH receptor dynamics, where pulsatile stimulation produces different downstream effects from continuous elevation.

IGF-1 Elevation and Anabolic Signalling

GH released by Ipamorelin drives hepatic IGF-1 production. IGF-1 (insulin-like growth factor 1) is the primary mediator of GH's anabolic effects: protein synthesis, muscle cell proliferation, connective tissue repair, and bone density. Research models using Ipamorelin to elevate IGF-1 study these downstream anabolic pathways in muscle, tendon, and bone tissue.

Body Composition Research

The GH → IGF-1 axis has well-established effects on body composition. Research with Ipamorelin in animal models has investigated its effects on lean mass preservation, fat mobilisation (particularly visceral fat), and changes in body composition ratios — separate from appetite or caloric intake mechanisms.

Sleep Architecture

The body's natural GH secretion is strongly linked to sleep — the largest GH pulse of the day occurs during slow-wave sleep. Ipamorelin's pulsatile release pattern has been studied in the context of sleep architecture research, with interest in whether GH secretagogue administration aligns with or amplifies the natural sleep-associated GH surge.

Recovery and Tissue Repair

IGF-1 signalling plays a central role in muscle satellite cell activation, connective tissue remodelling, and wound healing. Ipamorelin is used in preclinical recovery models to study these IGF-1 mediated repair processes in muscle and tendon after exercise-induced damage.

Ipamorelin vs CJC-1295: Complementary Not Competing

Because Ipamorelin and CJC-1295 act on completely separate receptor systems with no overlap, administering both produces GH output substantially greater than either compound alone. This synergistic combination is the most commonly used GH secretagogue stack in research protocols. Peptide Warehouse offers both compounds individually and as a pre-blended CJC-1295 + Ipamorelin 10mg vial.

Reconstitution and Storage

Add 1–2mL of bacteriostatic water to the lyophilised Ipamorelin vial. Inject BAC water slowly along the inside wall — do not inject directly onto the powder. Swirl gently until dissolved. The solution should be clear and colourless. Store lyophilised at −20°C for up to 24 months. Store reconstituted solution at 2–8°C for up to 4 weeks, protected from light.

Disclaimer: Ipamorelin is a research compound for in-vitro laboratory use only. Not for human consumption, therapeutic, or veterinary use. All information relates to preclinical research findings.